Biopharma Business

Tag "Sato Pharmaceutical"

Sterile Manufacturing Deviations Found at Japan Facility

On Feb. 2, 2017, FDA issued a warning letter to Sato Pharmaceutical Co., Ltd. after inspectors found current good manufacturing practices (CGMP) violations at the company’s Tokyo facility. Violations found

Read Full Article

Upcoming Events


The Magazine

New Subscriber

Subscribe Here